Navigation
User login
Podcast Subscription
Upcoming events
- European Supply Chain and Logistics Summit 2008(3 days)
- European Supply Chain Distinction Awards 2008(4 days)
- Biomarker Wolrd Congress 2008(10 days)
- 6th Annual Pharma Finance 2008(12 days)
- IBIC 2008(29 days)
- European PLM Summit(45 days)
News Feed
QuantRx Announces Exclusive Manufacturing and Distribution Agreement for New Presumptive Field Narcotics Testing Products with Fieldtests LLC (Business Wire)
DOYLESTOWN, Pa.----QuantRx Biomedical Corporation, , a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has concluded the development of the Fieldtests ID product line for identifying drugs-of-abuse residue.
Categories: Client Feeds
QuantRx Announces Expansion of its Molecular Imaging Technology Platform for Development of Diagnosis and Treatment Agents for Alzheimer's Disease (AD) (Business Wire)
DOYLESTOWN, Pa.----QuantRx Biomedical Corporation, , a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that its molecular imaging group, FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, has entered into a license agreement with Massachusetts General Hospital for the development and commercialization of agents for diagnosis and treatment of Alzheimer's disease .
Categories: Client Feeds
QuantRx Announces Commencement of Phase I Clinical Trial by FluoroPharma for BFPET(TM), A Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) (Business Wire)
DOYLESTOWN, Pa.----QuantRx Biomedical Corporation, , a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, is commencing Phase I clinical trials for BFPET following institutional review board approval of the proposed studies.
Categories: Client Feeds
QuantRx(R) Biomedical Announces Expansion of Its International Intellectual Property (Marketwire)
Categories: Client Feeds
QuantRx(R) Biomedical Announces MOU Agreement With Jant Pharmacal (Marketwire)
Categories: Client Feeds
QuantRx(R) Biomedical Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET) (Marketwire)
Categories: Client Feeds
QUANTRX BIOMEDICAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia (EDGAR Online)
Categories: Client Feeds
QuantRx(R) Biomedical Announces FluoroPharma to Present Results of CardioPET Phase I Trial at Society of Nuclear Medicine High Country Conference (Marketwire)
Categories: Client Feeds
QuantRx(R) Biomedical Announces Second Agreement With ALT BioScience to Develop Diagnostic Tests for Oral Health (Marketwire)
Categories: Client Feeds
QUANTRX BIOMEDICAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia (EDGAR Online)
Categories: Client Feeds
QUANTRX BIOMEDICAL CORP Files SEC form 8-K, Termination of a Material Definitive Agreement (EDGAR Online)
Categories: Client Feeds
QUANTRX BIOMEDICAL CORP Files SEC form 10QSB, Quarterly Report (EDGAR Online)
Categories: Client Feeds
QuantRx(R) Biomedical Announces the Launch of Affirm(R); Its Lateral Flow Rapid Drug Test Product Line (Marketwire)
Categories: Client Feeds
QuantRx Biomedical Corporation Announces FDA 510(k) Clearance for Its Follicle Stimulating Hormone (FSH) Immunoassay Test (Marketwire)
Categories: Client Feeds
QUANTRX BIOMEDICAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia (EDGAR Online)
Categories: Client Feeds
QuantRx Biomedical to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference (Marketwire)
Categories: Client Feeds
[video] Biotech Player HALO Is Golden, Says Hedge Fund Manager (at TheStreet.com)
Categories: Client Feeds
PF2008 Sponsored By
Who's online
There are currently 1 user and 320 guests online.
